279 related articles for article (PubMed ID: 8951903)
1. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.
Huić D; Medvedec M; Dodig D; Popović S; Ivancević D; Pavlinovic Z; Zuvic M
Nucl Med Commun; 1996 Oct; 17(10):839-42. PubMed ID: 8951903
[TBL] [Abstract][Full Text] [Related]
2. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
3. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2004 Apr; 45(4):619-25. PubMed ID: 15073258
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry.
Yeung HW; Humm JL; Larson SM
J Nucl Med; 2000 Jun; 41(6):1082-5. PubMed ID: 10855639
[TBL] [Abstract][Full Text] [Related]
5. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
6. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
[TBL] [Abstract][Full Text] [Related]
7. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
Bajén MT; Mañé S; Muñoz A; García JR
J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
[TBL] [Abstract][Full Text] [Related]
8. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
9. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
[TBL] [Abstract][Full Text] [Related]
10. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
Moser E; Fritsch S; Braun S
Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
[TBL] [Abstract][Full Text] [Related]
12. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study.
Hoyes KP; Owens SE; Millns MM; Allan E
Nucl Med Commun; 2004 Mar; 25(3):245-51. PubMed ID: 15094442
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
[TBL] [Abstract][Full Text] [Related]
14. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
[TBL] [Abstract][Full Text] [Related]
15. Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake.
Chopra S; Wastie ML; Chan S; Vincent RM; Przeslak A; Perkins AC; Ubhi CS
Nucl Med Commun; 1996 Aug; 17(8):687-91. PubMed ID: 8878128
[TBL] [Abstract][Full Text] [Related]
16. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
17. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy.
de Klerk JM; de Keizer B; Zelissen PM; Lips CM; Koppeschaar HP
Nucl Med Commun; 2000 Jun; 21(6):529-32. PubMed ID: 10894561
[TBL] [Abstract][Full Text] [Related]
18. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
[TBL] [Abstract][Full Text] [Related]
19. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
20. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]